Search research articles
Contact Us
Filters
Showing results (1-10 of 477) with videos related to
Page
of 48
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 23, 2017
Circulating Tumor Cell Eradication as an Intermediate Efficacy End Point for Metastatic Castration-Resistant Prostate Cancer: Is There Enough Evidence?
Emmanuel S Antonarakis
The Journal of Urology
|
October 9, 2016
Editorial Comment
Emmanuel S Antonarakis
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 13, 2018
Reply to C. Ren et al
Emmanuel S Antonarakis
The Lancet. Oncology
|
August 31, 2016
Inherited HSD3B1 polymorphisms and hormonal therapy resistance
Emmanuel S Antonarakis
Asian Journal of Andrology
|
July 12, 2011
Abiraterone acetate for prostate cancer: a new era of hormonal therapies
Emmanuel S Antonarakis
The Lancet. Oncology
|
June 9, 2018
Abiraterone plus olaparib in prostate cancer: a new form of synthetic lethality?
Emmanuel S Antonarakis
The Lancet. Oncology
|
September 14, 2019
Targeting lineage plasticity in prostate cancer
Emmanuel S Antonarakis
Cancers
|
January 19, 2018
AR Signaling in Human Malignancies: Prostate Cancer and Beyond
Emmanuel S Antonarakis
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
|
June 30, 2007
Visual vignette. Necrobiosis lipoidica
Emmanuel S Antonarakis
European Urological Review
|
June 22, 2013
Management of metastatic castration-resistant prostate cancer
Emmanuel S Antonarakis
Page
of 48
Search research articles
Search
Showing results (1-10 of 477) with videos related to
Sort By:
Page
of 48
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 23, 2017
Circulating Tumor Cell Eradication as an Intermediate Efficacy End Point for Metastatic Castration-Resistant Prostate Cancer: Is There Enough Evidence?
Emmanuel S Antonarakis
The Journal of Urology
|
October 9, 2016
Editorial Comment
Emmanuel S Antonarakis
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 13, 2018
Reply to C. Ren et al
Emmanuel S Antonarakis
The Lancet. Oncology
|
August 31, 2016
Inherited HSD3B1 polymorphisms and hormonal therapy resistance
Emmanuel S Antonarakis
Asian Journal of Andrology
|
July 12, 2011
Abiraterone acetate for prostate cancer: a new era of hormonal therapies
Emmanuel S Antonarakis
The Lancet. Oncology
|
June 9, 2018
Abiraterone plus olaparib in prostate cancer: a new form of synthetic lethality?
Emmanuel S Antonarakis
The Lancet. Oncology
|
September 14, 2019
Targeting lineage plasticity in prostate cancer
Emmanuel S Antonarakis
Cancers
|
January 19, 2018
AR Signaling in Human Malignancies: Prostate Cancer and Beyond
Emmanuel S Antonarakis
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
|
June 30, 2007
Visual vignette. Necrobiosis lipoidica
Emmanuel S Antonarakis
European Urological Review
|
June 22, 2013
Management of metastatic castration-resistant prostate cancer
Emmanuel S Antonarakis
Page
of 48